soul trial oral semaglutide cardiovascular outcomes results 2025 nejm 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM In patients with type 2

Its two RLT products Lutathera (lutetium-177 DOTATATE) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and Pluvicto (lutetium-177 PSMA-617) for metastatic castration-resistant prostate cancer represent the most commercially advanced radioligand therapy platform in the world and occupy the Oncology Peptide Therapy segment, which the report forecasts to grow at 11.79% CAGR through 2031

Pure Med Spa is proud to offer a high-quality, patient-centered program that emphasizes individualized treatment plans, licensed providers, and continuous support

But patches are different

We know about side effects such as nausea, vomiting and digestive problems, but what about longer-term outcomes

Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, et al

Signs of Skin Inflammation and Acne-Related Marks Skin inflammation often manifests as visible and textural changes on the face and body, especially when acne triggers prolonged immune responses in the skin